TW200738645A - Use of 4-imidazole derivatives for CNS disorders - Google Patents
Use of 4-imidazole derivatives for CNS disordersInfo
- Publication number
- TW200738645A TW200738645A TW096102837A TW96102837A TW200738645A TW 200738645 A TW200738645 A TW 200738645A TW 096102837 A TW096102837 A TW 096102837A TW 96102837 A TW96102837 A TW 96102837A TW 200738645 A TW200738645 A TW 200738645A
- Authority
- TW
- Taiwan
- Prior art keywords
- disorders
- phenyl
- lower alkyl
- halogen
- lower alkoxy
- Prior art date
Links
- 208000015114 central nervous system disease Diseases 0.000 title 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 208000035475 disorder Diseases 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000017164 Chronobiology disease Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 208000002249 Diabetes Complications Diseases 0.000 abstract 1
- 206010012655 Diabetic complications Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
- 230000036760 body temperature Effects 0.000 abstract 1
- 230000027288 circadian rhythm Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000005265 energy consumption Methods 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 230000013632 homeostatic process Effects 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- -1 hydroxy, phenyl Chemical group 0.000 abstract 1
- 230000007257 malfunction Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 230000007958 sleep Effects 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06100938 | 2006-01-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200738645A true TW200738645A (en) | 2007-10-16 |
Family
ID=38051581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW096102837A TW200738645A (en) | 2006-01-27 | 2007-01-25 | Use of 4-imidazole derivatives for CNS disorders |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8158668B2 (zh) |
| EP (1) | EP1981880B1 (zh) |
| JP (1) | JP2009524616A (zh) |
| KR (1) | KR101079914B1 (zh) |
| CN (1) | CN101374832B (zh) |
| AR (1) | AR059206A1 (zh) |
| AT (1) | ATE458732T1 (zh) |
| AU (1) | AU2007209380B2 (zh) |
| BR (1) | BRPI0706759A2 (zh) |
| CA (1) | CA2637308C (zh) |
| DE (1) | DE602007004949D1 (zh) |
| ES (1) | ES2338716T3 (zh) |
| IL (1) | IL192885A0 (zh) |
| NO (1) | NO20083356L (zh) |
| RU (1) | RU2008130448A (zh) |
| TW (1) | TW200738645A (zh) |
| WO (1) | WO2007085556A2 (zh) |
| ZA (1) | ZA200806457B (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI629066B (zh) * | 2013-10-07 | 2018-07-11 | 帝國製藥美國股份有限公司 | 使用右美托咪啶經皮組成物用於治療注意力不足過動症、焦慮及失眠的方法及組成物 |
| US10772871B2 (en) | 2013-10-07 | 2020-09-15 | Teikoku Pharma Usa, Inc. | Dexmedetomidine transdermal delivery devices and methods for using the same |
| US10987342B2 (en) | 2013-10-07 | 2021-04-27 | Teikoku Pharma Usa, Inc. | Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine |
| US12527770B2 (en) | 2016-10-31 | 2026-01-20 | Teikoku Pharma Usa, Inc. | Methods of managing pain using dexmedetomidine transdermal delivery devices |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2637312A1 (en) | 2006-01-27 | 2007-08-02 | F. Hoffmann-La Roche Ag | Use of substituted 2-imidazole of imidazoline derivatives |
| EP2076497B1 (en) | 2006-10-19 | 2012-02-22 | F. Hoffmann-La Roche AG | Aminomethyl-4-imidazoles |
| CA2675221C (en) | 2007-02-02 | 2016-02-23 | F. Hoffmann-La Roche Ag | Novel 2-aminooxazolines as taar1 ligands |
| EP2125749A2 (en) | 2007-02-13 | 2009-12-02 | Schering Corporation | Functionally selective alpha2c adrenoreceptor agonists |
| CL2008000431A1 (es) * | 2007-02-13 | 2008-08-18 | Schering Corp | Compuestos derivados de biciclos o heterociclos condensados; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar afecciones relacionadas con los a2c adrenegicos, tales como congestion relacionada con rinitis, polipos o re |
| WO2008100459A1 (en) | 2007-02-13 | 2008-08-21 | Schering Corporation | Derivatives and analogs of chroman as functionally selective alpha2c adrenoreceptor agonists |
| WO2009003867A1 (en) * | 2007-07-03 | 2009-01-08 | F. Hoffmann-La Roche Ag | 4-imidazolines and their use as antidepressants |
| US7902247B2 (en) * | 2008-01-09 | 2011-03-08 | Allergan, Inc. | Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors |
| DK2250153T3 (da) * | 2008-01-18 | 2013-09-16 | Allergan Inc | Substituerede aryl-(imidazol)-methyl)-phenylforbindelser som subtype-selektive modulatorer af alpha 2b og/eller alpha 2 c-adrenerge receptorer |
| US8242153B2 (en) | 2008-07-24 | 2012-08-14 | Hoffmann-La Roche Inc. | 4,5-dihydro-oxazol-2YL derivatives |
| PE20110215A1 (es) * | 2008-07-24 | 2011-03-31 | Hoffmann La Roche | Derivados de 4,5-dihidro-oxazol-2-ilo |
| CA2772354A1 (en) * | 2009-08-26 | 2011-03-10 | Daniel W. Gil | Method of treating compulsive disorders with alpha-2b adrenergic receptor agonists |
| UY32858A (es) | 2009-08-31 | 2011-03-31 | Abbott Healthcare Products Bv | Derivados de (tio)morfolina como moduladores de sip |
| US8354441B2 (en) | 2009-11-11 | 2013-01-15 | Hoffmann-La Roche Inc. | Oxazoline derivatives |
| US9452980B2 (en) | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
| TWI543984B (zh) | 2010-07-09 | 2016-08-01 | 艾伯維公司 | 作為s1p調節劑的螺-哌啶衍生物 |
| AR090557A1 (es) | 2012-04-02 | 2014-11-19 | Orion Corp | DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2 |
| ES2665619T3 (es) | 2013-03-14 | 2018-04-26 | Novartis Ag | 3-Pirimidin-4-il-oxazolidin-2-onas como inhibidores de IDH mutante |
| CN103664788B (zh) * | 2013-12-04 | 2015-11-25 | 湖北生物医药产业技术研究院有限公司 | 制备美托咪啶的方法 |
| EP3411375B1 (en) | 2016-02-04 | 2020-08-05 | Chiesi Farmaceutici S.p.A. | Pyrazole derivatives as phosphoinositide 3-kinases inhibitors |
| PT3430010T (pt) | 2016-03-17 | 2020-09-10 | Hoffmann La Roche | Derivado de 5-etiol-4-metil-pirazol-3-carboxamida com atividade de agonista de taar |
| CN105884691B (zh) * | 2016-06-02 | 2017-08-25 | 江苏恒瑞医药股份有限公司 | 一种制备右美托咪定及其中间体的方法 |
| EP3634406B1 (en) * | 2017-05-12 | 2023-09-06 | Board of Trustees of The Southern Illinois University on behalf of Southern Illinois University Edwardsville | 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof |
| CN107879979B (zh) * | 2017-10-27 | 2020-08-25 | 广东莱佛士制药技术有限公司 | 一种右美托咪定的制备方法 |
| CA3159378A1 (en) | 2019-10-31 | 2021-05-06 | ESCAPE Bio, Inc. | Solid forms of an s1p-receptor modulator |
| CN121219269A (zh) * | 2023-05-24 | 2025-12-26 | 江苏恩华药业股份有限公司 | 一种咪唑衍生物、中间体、制备方法及其应用 |
| WO2024260319A1 (zh) * | 2023-06-19 | 2024-12-26 | 江苏恩华药业股份有限公司 | 一种取代咪唑衍生物、中间体、制备方法及其应用 |
| CN120787220A (zh) * | 2024-02-04 | 2025-10-14 | 成都麻沸散医药科技有限公司 | 一种杂环化合物及其制药用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7312245A (nl) * | 1973-09-06 | 1975-03-10 | Stamicarbon | Werkwijze voor het bereiden van alphamethylstyreen bevattende blokcopolymeren. |
| AU518569B2 (en) * | 1979-08-07 | 1981-10-08 | Farmos-Yhtyma Oy | 4-benzyl- and 4-benzoyl imidazole derivatives |
| GB2101114B (en) * | 1981-07-10 | 1985-05-22 | Farmos Group Ltd | Substituted imidazole derivatives and their preparation and use |
| JPH0733333B2 (ja) * | 1986-12-12 | 1995-04-12 | 三井石油化学工業株式会社 | 脳機能改善薬 |
| GB2215206B (en) * | 1988-02-29 | 1991-07-03 | Farmos Oy | 4-substituted imidazole derivatives useful in perioperative care |
| FI894911A0 (fi) * | 1989-10-17 | 1989-10-17 | Farmos Oy | En terapeutiskt vaerdefull foerening. |
| GB2256135B (en) | 1991-05-31 | 1995-01-18 | Orion Yhtymae Oy | Transdermal administration of 4-substituted imidazoles |
| GB9521680D0 (en) | 1995-10-23 | 1996-01-03 | Orion Yhtymo Oy | New use of imidazole derivatives |
| IL136388A0 (en) * | 1997-12-04 | 2001-06-14 | Allergan Sales Inc | Substituted imidazole derivatives having agonist-like activity at alpha 2b or 2b/2c adrenergic receptors |
| US6573289B1 (en) * | 1998-04-23 | 2003-06-03 | Takeda Chemical Industries, Ltd. | Naphthalene derivatives, their production and use |
| JP4546589B2 (ja) * | 1998-04-23 | 2010-09-15 | 武田薬品工業株式会社 | ナフタレン誘導体 |
| PE20010781A1 (es) * | 1999-10-22 | 2001-08-08 | Takeda Chemical Industries Ltd | Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion |
| JP4520012B2 (ja) * | 1999-10-22 | 2010-08-04 | 武田薬品工業株式会社 | １−置換−１−（１ｈ−イミダゾール−４−イル）メタノール類 |
| IL147921A0 (en) * | 2002-01-31 | 2002-08-14 | Abdulrazik Mohammad | A method for treating central nervous system disorders by ocular dosing |
| CN1849308A (zh) * | 2003-07-09 | 2006-10-18 | 弗·哈夫曼-拉罗切有限公司 | 硫代苯基氨基咪唑啉 |
| JP5165242B2 (ja) * | 2003-09-12 | 2013-03-21 | アラーガン、インコーポレイテッド | 疼痛およびα２アドレナリン受容体が関与する他の状態の処置のための方法および組成物 |
| WO2006036480A1 (en) * | 2004-09-24 | 2006-04-06 | Allergan, Inc. | 4-(phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adrenergic agonists |
-
2007
- 2007-01-17 AT AT07703939T patent/ATE458732T1/de active
- 2007-01-17 RU RU2008130448/04A patent/RU2008130448A/ru not_active Application Discontinuation
- 2007-01-17 CA CA2637308A patent/CA2637308C/en not_active Expired - Fee Related
- 2007-01-17 JP JP2008551759A patent/JP2009524616A/ja active Pending
- 2007-01-17 ES ES07703939T patent/ES2338716T3/es active Active
- 2007-01-17 EP EP07703939A patent/EP1981880B1/en not_active Not-in-force
- 2007-01-17 CN CN2007800036567A patent/CN101374832B/zh not_active Expired - Fee Related
- 2007-01-17 DE DE602007004949T patent/DE602007004949D1/de active Active
- 2007-01-17 AU AU2007209380A patent/AU2007209380B2/en not_active Ceased
- 2007-01-17 KR KR1020087020817A patent/KR101079914B1/ko not_active Expired - Fee Related
- 2007-01-17 BR BRPI0706759-3A patent/BRPI0706759A2/pt not_active IP Right Cessation
- 2007-01-17 WO PCT/EP2007/050441 patent/WO2007085556A2/en not_active Ceased
- 2007-01-19 US US11/655,539 patent/US8158668B2/en not_active Expired - Fee Related
- 2007-01-25 TW TW096102837A patent/TW200738645A/zh unknown
- 2007-01-26 AR ARP070100342A patent/AR059206A1/es unknown
-
2008
- 2008-07-17 IL IL192885A patent/IL192885A0/en unknown
- 2008-07-24 ZA ZA200806457A patent/ZA200806457B/xx unknown
- 2008-07-31 NO NO20083356A patent/NO20083356L/no not_active Application Discontinuation
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI629066B (zh) * | 2013-10-07 | 2018-07-11 | 帝國製藥美國股份有限公司 | 使用右美托咪啶經皮組成物用於治療注意力不足過動症、焦慮及失眠的方法及組成物 |
| US10772871B2 (en) | 2013-10-07 | 2020-09-15 | Teikoku Pharma Usa, Inc. | Dexmedetomidine transdermal delivery devices and methods for using the same |
| US10874642B2 (en) | 2013-10-07 | 2020-12-29 | Teikoku Pharma Usa, Inc. | Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions |
| US10987342B2 (en) | 2013-10-07 | 2021-04-27 | Teikoku Pharma Usa, Inc. | Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine |
| US12527770B2 (en) | 2016-10-31 | 2026-01-20 | Teikoku Pharma Usa, Inc. | Methods of managing pain using dexmedetomidine transdermal delivery devices |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2637308A1 (en) | 2007-08-02 |
| DE602007004949D1 (de) | 2010-04-08 |
| WO2007085556A2 (en) | 2007-08-02 |
| US20070197622A1 (en) | 2007-08-23 |
| BRPI0706759A2 (pt) | 2011-04-05 |
| CN101374832A (zh) | 2009-02-25 |
| KR20080088658A (ko) | 2008-10-02 |
| ZA200806457B (en) | 2009-11-25 |
| EP1981880A2 (en) | 2008-10-22 |
| KR101079914B1 (ko) | 2011-11-04 |
| EP1981880B1 (en) | 2010-02-24 |
| ATE458732T1 (de) | 2010-03-15 |
| CN101374832B (zh) | 2013-03-06 |
| AU2007209380B2 (en) | 2011-12-08 |
| CA2637308C (en) | 2014-02-25 |
| JP2009524616A (ja) | 2009-07-02 |
| AU2007209380A1 (en) | 2007-08-02 |
| US8158668B2 (en) | 2012-04-17 |
| RU2008130448A (ru) | 2010-03-10 |
| ES2338716T3 (es) | 2010-05-11 |
| IL192885A0 (en) | 2009-02-11 |
| AR059206A1 (es) | 2008-03-19 |
| NO20083356L (no) | 2008-10-21 |
| WO2007085556A3 (en) | 2007-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200738645A (en) | Use of 4-imidazole derivatives for CNS disorders | |
| UA98951C2 (ru) | 2-аминооксазолины и лекарственное средство, которое их содержит | |
| TW200833685A (en) | Aminomethyl-4-imidazoles | |
| TW200738690A (en) | Use of 2-imidazoles for the treatment of CNS disorders | |
| TW200738233A (en) | Use of substituted 2-imidazole or imidazoline derivatives | |
| MY176030A (en) | Substituted benzamide derivatives | |
| CN1419552A (zh) | 2－氨基－3－烷基嘧啶酮衍生物作为GSK3β抑制剂 | |
| PH12013501905A1 (en) | Heterocyclic amine derivatives | |
| CO6331336A2 (es) | Derivados de 4,5-dihidro-oxazol-2-ilo | |
| PH12013502315A1 (en) | Pyrazole derivatives | |
| AR067772A1 (es) | Derivados piperazinicos de nicotinamida, medicamentos que los contienen, proceso para prepararlos y usos de los mismos para el tratamiento de trastornos asociados al sistema nervioso, cardiovascular y/o trastornos metabolicos. | |
| WO2009003868A3 (en) | 2 -imidazolines having a good affinity to the trace amine associated receptors (taars) | |
| PH12013502263A1 (en) | Substituted benzamide derivatives | |
| EP2903980A1 (en) | Benzimidazoles as cns active agents | |
| WO2014079787A1 (en) | Substituted 1,6-naphthyridines | |
| MX378486B (es) | Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo. | |
| MX354815B (es) | Derivados heterociclicos como receptores asociados con las aminas traza (taars). | |
| US20160137643A1 (en) | 1,7-naphthyridine derivatives | |
| WO2007090720A3 (en) | Use of 2-imidazoles for the treatment of cns disorders | |
| MX2009005920A (es) | Nuevos 2-imidazoles como ligandos para receptores asociados con trazas de amina. | |
| MX2009006215A (es) | 4-imidazolinas como ligandos de aminas trazas. | |
| MX377195B (es) | Derivados de morfolina-piridina. | |
| MX2015005721A (es) | Derivados de pirazina. | |
| AR076979A1 (es) | 2- aminooxazolinas como ligandos de taar1 | |
| NO20091721L (no) | Substituerte 4-imidazoler |